Research
Hormonal
Women diagnosed with breast cancer can safely consume soyfoods without increasing the risk of recurrence or mortality, and post-diagnosis soy intake may be associated with a decreased risk of recurrence.
If you have had breast cancer, you can eat soyfoods. They are safe and do not increase your risk of the cancer coming back. Some studies even suggest they might help, but you shouldn't start eating them just to treat the cancer—just include them as part of a healthy diet.
GoodQualifiesHIGH confidence
The totality of the evidence is aligned with the positions of health agencies that women diagnosed with BCa can safely consume soyfoods. Although suggestive, the observational data do not provide a sufficient basis for recommending BCa patients begin consuming soy specifically to improve prognosis.
Why this rating
Based on multiple prospective observational studies, meta-analyses, and clinical trials showing no adverse effects on proliferation.
Source
The health effects of soy: A reference guide for health professionals
Mark Messina et al. · Frontiers in Nutrition · 2022
DOI 10.3389/fnut.2022.970364
narrative_reviewCited 61×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Soy protein promotes gains in muscle mass and strength during resistance exercise training similarly to whey and other animal proteins, despite acute studies showing whey stimulates muscle protein synthesis more strongly.Good
- Soy protein has a high quality score (PDCAAS ~1.0 and DIAAS up to 117%) and is as effective as animal proteins for weight management and satiety.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →